UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 13, 2010 (September 13, 2010)
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Florida (State or other jurisdiction of incorporation) |
001-33357 (Commission File Number) |
65-0643773 (IRS Employer Identification No.) |
| 2 Snunit Street | 20100 | |
| Science Park, POB 455 | ||
| Carmiel, Israel | ||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Ruled-2(b) |
| o | Pre-commencement communications pursuant to Rulee-4(c) |
| Item 7.01. | Regulation FD Disclosure |
On September 13, 2010, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing that Dr. David Aviezer, the Company’s President and Chief Executive Officer, will
present at the UBS Global Life Sciences Conference on September 20, 2010 at 10:30 AM, ET. The
conference is being held at the Grand Hyatt Hotel in New York City from September 20 through
September 22, 2010. A copy of the press release is furnished as Exhibit 99.1.
An audio webcast of the presentation will be available on the Company’s website,
www.protalix.com, on the event calendar page.
The information in Item 7.01 of this report (including Exhibit 99.1) is being furnished pursuant to
Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of
that section, nor shall it be deemed to be incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press release dated September 13, 2010. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROTALIX BIOTHERAPEUTICS, INC. |
||||
| Date: September 13, 2010 | By: | /s/ David Aviezer | ||
| Name: | David Aviezer, Ph.D. | |||
| Title: | President and Chief Executive Officer | |||
3
Exhibit 99.1
Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference
CARMIEL, Israel, September 13, 2010 (PR NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-AMEX:
PLX, TASE:PLX), announced today that Dr. David Aviezer, Protalix’s president and CEO, will present
at the UBS Global Life Sciences Conference on September 20, 2010 at 10:30 AM ET. The conference is
being held September 20 — 22, 2010 at the Grand Hyatt Hotel in New York City.
An audio webcast of the presentation will be available on Protalix’s website,
www.protalix.com, on the event calendar page.
About Protalix
Protalix is a biopharmaceutical company focused on the development and commercialization of
proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based
expression system. Protalix’s ProCellEx™ presents a proprietary method for the expression of
recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale
production of recombinant therapeutic proteins in an environment free of mammalian components and
viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development
programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special
Protocol Assessment with the FDA for Gaucher disease. The Company’s new drug application (NDA) for
taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a
Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Investor Contact:
Marcy Nanus
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com
Marcy Nanus
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com